Common name
fluorobenzene
IUPAC name
fluorobenzene
SMILES
Fc1ccccc1
Common name
fluorobenzene
IUPAC name
fluorobenzene
SMILES
Fc1ccccc1
INCHI
InChI=1S/C6H5F/c7-6-4-2-1-3-5-6/h1-5H
FORMULA
C6H5F
Common name
fluorobenzene
IUPAC name
fluorobenzene
Molecular weight
96.102
clogP
2.398
clogS
-1.833
Frequency
0.0237
HBond Acceptor
0
HBond Donor
0
Total PolarSurface Area
0
Number of Rings
1
Rotatable Bond
0
| Drug ID | Common name | Structure CAS | Compound class | Therapeutic area |
|---|---|---|---|---|
| FDBD01581 | Riociguat |
|
Riociguat is indicated for the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH), (WHO Group 4) after surgical treatment, or inoperable CTEPH, to improve exercise capacity and WHO functional class. | |
| FDBD01602 | Flubendazole |
|
Antinematodal Agents; Anthelmintics; Antiparasitic Products, Insecticides and Repellents; Benzimidazole Derivatives; Benzimidazoles and Related Substances; | |
| FDBD01636 | Vorapaxar |
|
Platelet Aggregation Inhibitors; Antithrombotic Agents; Blood and Blood Forming Organs; Platelet Aggregation Inhibitors Excl. Heparin; | Vorapaxar is indicated for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or peripheral arterial disease (PAD). It is usually co-administered with acetylsalicylic acid (ASA) and/or clopidogrel, and should therefore be administered as an addition to these medications as it has not been studied alone. |
| FDBD01643 | Tedizolid Phosphate |
|
Anti-Bacterial Agents; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; | Tedizolid Phosphate is an oxazolidinone antibacterial drug indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-resistant [MRSA] and methicillin-susceptible [MSSA] isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus Group (including Streptococcus anginosus, Streptococcus intermedius, and Streptococcus constellatus), and Enterococcus faecalis. |
| FDBD01658 | Olaparib |
|
Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inhibitors; CYP2B6 Inhibitors (strong); CYP3A4 Inhibitors; Poly(ADP-ribose) Polymerase Inhibitors; | Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated as monotherapy in patients with deleterious or suspected deleterious germline BRCA mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. |
| FDBD01718 | Flutemetamol (18F) |
|
Diagnostic Radiopharmaceuticals; Central Nervous System; | |
| FDBD01751 | Blonanserin |
|
; | Used for the treatment of schizophrenia. |
| FDBD01752 | Melperone |
|
Antipsychotic Agents; Nervous System; Psycholeptics; Butyrophenone Derivatives; | For the treatment of schizophrenia. |
| FDBD01784 | Pipamperone |
|
Antipsychotic Agents; Nervous System; Psycholeptics; Butyrophenone Derivatives; | Used in the treatment of schizophrenia. |
| FDBD01976 | flufenoxuron |
|
Insecticide | Insecticide |
69 ,
7
| FRAGNAME | PDBID | SIMILIRITY | XSCORE | SMILE | HAC |
|---|---|---|---|---|---|
| 1xkk_ligand_frag_10.mol2 | 1xkk | 1 | -6.81 | c1cccc(F)c1 | 7 |
| 2rgp_ligand_frag_0.mol2 | 2rgp | 1 | -6.79 | c1ccccc1F | 7 |
| 3bel_ligand_frag_0.mol2 | 3bel | 1 | -6.78 | c1cc(ccc1)F | 7 |
| 2r4b_ligand_frag_0.mol2 | 2r4b | 1 | -6.77 | Fc1ccccc1 | 7 |
| 3fu0_ligand_frag_0.mol2 | 3fu0 | 1 | -6.77 | Fc1ccccc1 | 7 |
| 4l8m_ligand_frag_2.mol2 | 4l8m | 1 | -6.77 | Fc1ccccc1 | 7 |
| 1zz2_ligand_frag_5.mol2 | 1zz2 | 1 | -6.74 | c1ccc(cc1)F | 7 |
| 3bbt_ligand_frag_5.mol2 | 3bbt | 1 | -6.74 | c1cccc(F)c1 | 7 |
443 ,
45
